What is treatment-resistant depression (TRD)? Treatment-resistant depression (TRD) is a term used when depression symptoms have not improved enough after multiple well-delivered treatments. Many clinical definitions focus on inadequate improvement after at least two antidepressant trials at appropriate dose and duration, but definitions differ across guidelines and research studies.¹–⁴ That variation matters. If two clinics use different definitions, the same person might be labeled “TRD” in one setting and “difficult-to-treat” in another, even with the same lived experience. A steady first step is to ask your clinician, “How are you defining TRD for me, and what treatments count in that definition?”¹–⁴ How is TRD related to major depressive disorder (MDD)? Major depressive disorder (MDD) is diagnosed by a pattern of symptoms, not a single lab test. A major depressive episode is commonly described as at least two weeks of depressed mood or loss of interest or pleasure, along with other symptoms such as sleep or appetite changes, low energy, trouble concentrating, or low self-worth.⁵,⁶ TRD is not a separate diagnosis the way MDD is. It is a description of treatment response over time, meaning: the depression is present, the person has tried evidence-based treatments, and relief has been limited or short-lived.¹–⁴ What does an “adequate” treatment trial mean, and why does it matter? An “adequate trial” generally means the treatment was given a fair chance: enough dose, enough time, and enough follow-up to judge whether it helped. Guidelines emphasize checking this carefully, because a medication that “didn’t work” at a low dose for a short time may not truly represent a failed trial.²–⁴ This is where details become light in a dark room. A simple treatment history, name, dose, how long you took it, benefits, side effects, and why it stopped, can help a clinician avoid repeating what already failed and focus on what is genuinely next.²–⁴ Why might depression not respond to treatments that usually help? Sometimes the depression diagnosis is correct, but the plan is missing something potentiall hidden: bipolar disorder, trauma-related symptoms, substance use, untreated sleep disorders, chronic pain, thyroid problems, medication side effects, or other medical conditions can shape what treatments are safest and most effective.²,³,⁶ Other times, the issue is not “willpower,” it is mismatched treatment intensity or sequencing. Major guidelines stress systematic care, meaning: confirm diagnosis, measure symptoms over time, and adjust treatments step by step rather than drifting from one attempt to the next.²–⁴ What evaluations are commonly recommended before confirming TRD? Clinicians commonly re-check diagnosis and comorbidities, including screening for bipolar disorder, anxiety disorders, trauma-related conditions, and substance use, because these can change the treatment pathway.²,³ They also review treatment adequacy and adherence, and they look for medical contributors or medication interactions that could blunt response or worsen symptoms.²,³,⁶ If you are unsure what has been evaluated, an empowering question is: “What medical and mental health factors should we rule out before we call this treatment-resistant?”²,³ What is measurement-based care, and why is it emphasized in TRD? Measurement-based care means tracking symptoms with a consistent tool at regular intervals, then using that data to guide decisions. Major guidelines recommend this approach because it reduces guesswork and helps clinicians detect partial response, relapse, or side effects earlier.²,⁷ A widely used example is the PHQ-9, which has strong evidence as a brief measure of depression severity and change over time.⁸ Measurement does not replace your story, it supports it, like a lighthouse that helps you and your team see whether the tide is shifting.²,⁷,⁸ What are realistic goals when treating TRD? Guidelines often describe progress in levels: response (meaningful symptom reduction), remission (minimal or no symptoms), and recovery (remission that lasts).²–⁴ These terms can keep a plan grounded, because the goal is not only “feel better,” it is “how much better, by when, and how will we know?”²,⁷ For many people, the path is not a straight line. It can feel like moving through heavy water, then suddenly finding a pocket of air. A helpful clinician conversation is: “What outcome are we aiming for next, and what is our plan if we do not reach it?”²–⁴ What medication approaches are commonly used when depression does not improve? After an initial antidepressant does not help enough, guidelines describe structured options such as optimizing the current dose, switching antidepressants, combining certain antidepressants in selected situations, or using augmentation.²–⁴ Augmentation means adding a medication to boost the antidepressant effect rather than replacing it.²–⁴ Evidence-based augmentation options can include certain second-generation antipsychotics, lithium, or thyroid hormone in carefully selected situations, with monitoring for side effects and interactions.²–⁴ Because these choices are individualized to each person, having decision-support questions can help such as: “What benefit do we expect, what risks matter most for me, and what monitoring schedule will we use?”²–⁴ What role does psychotherapy play in TRD? Psychotherapy is a core treatment for depression, and guidelines support it both as a stand-alone option for some people and as a combined approach with medication for others.²–⁴ Evidence-based therapies include structured approaches such as cognitive behavioral therapy (CBT), and guidelines also discuss relapse-prevention strategies.²,³ In TRD, psychotherapy can also support coping with the exhaustion of repeated trials, sleep disruption, avoidance patterns, and the isolation that depression can create. This is not about blaming the person. It is about strengthening skills and support while biological and neuromodulation options are considered.²–⁴ What is electroconvulsive therapy (ECT), and when is it considered? ECT is a medical procedure performed under anesthesia in which a controlled electrical stimulus triggers a brief seizure. It is typically considered for severe depression, depression that has not improved after other treatments, or situations where a rapid response is needed because risk is high.²,³,⁹ ECT has important tradeoffs. Common short-term side effects can include headache, nausea, fatigue, confusion, and memory problems, and people vary in how they experience cognitive effects.¹⁰,¹¹ If ECT is discussed, ask why is ECT now and option, what type of ECT is would be planned, and how will your medical team monitor memory and thinking during and after treatment?”⁹–¹¹ What is transcranial magnetic stimulation (TMS), and how does it fit into TRD care? TMS is a noninvasive treatment that uses magnetic pulses to stimulate nerve cells in brain networks involved in mood. It is delivered in repeated sessions, typically in an outpatient clinic, and it is often considered when other depression treatments have not been effective enough.²,³,¹² In the United States, the FDA cleared the first TMS device for adults with major depressive disorder who did not improve with at least one antidepressant in the current episode (a device-specific indication).¹³ More recent practice includes multiple protocols and dosing strategies, so it helps to ask: “Which protocol are you recommending, how many sessions, and what would count as enough improvement to continue?”²,³,¹² What is esketamine (Spravato), and what makes it different? Esketamine is a nasal spray that acts on glutamate pathways rather than the more common serotonin or norepinephrine pathways. The FDA label includes use for treatment-resistant depression in adults, and it must be administered under healthcare supervision with required monitoring due to known risks such as sedation and dissociation.¹⁴ Esketamine is not the same as unsupervised ketamine products marketed online. If it is being considered, practical questions include: “What does a treatment visit involve, what side effects are most common, and how will we evaluate benefit after the initial phase?”¹⁴ What is vagus nerve stimulation (VNS) for depression, and what does the evidence say? VNS for depression involves an implanted device that stimulates the vagus nerve in the neck, sending signals to brain circuits involved in mood regulation. In the US, the FDA approved VNS for adjunctive long-term treatment of chronic or recurrent depression in adults who have not had an adequate response to multiple antidepressant treatments.¹⁵,¹⁶ VNS is generally described as a longer-horizon treatment, meaning improvements, when they occur, may build gradually rather than immediately. Because it involves surgery and ongoing device programming, decision-support questions matter: “What is the expected timeline, what are the surgical risks, and how will programming and follow-up work at this center?”¹⁵,¹⁶ What is deep brain stimulation (DBS), and is it approved for TRD? DBS is a surgical therapy that implants electrodes into specific brain regions and connects them to an implanted pulse generator. It sends electrical pulses to targeted brain circuits, and it requires brain imaging and careful surgical planning.⁹,¹⁷ DBS is well established for certain neurologic conditions, but for depression it is generally considered investigational and is typically available through research studies and clinical trials rather than routine care.⁹ Research results have been mixed across study designs, and the field continues to refine targets and patient selection.¹⁸–²¹ What does DBS research for TRD suggest so far, and what remains uncertain? Several reviews and pooled analyses report that some people receiving DBS for TRD experience meaningful symptom improvement over time, while others do not, and outcomes can depend on study design, target, and how stimulation is optimized.¹⁸–²¹ In some lines of research, especially targeting the subcallosal cingulate region, investigators describe the need for careful, sometimes lengthy, adjustment of stimulation settings to reach stable benefit.²⁰,²¹ Important uncertainty remains. Sham-controlled trials have not always shown clear separation between active and control groups, and researchers continue working to understand who is most likely to benefit, how to choose targets, and how to measure improvement more objectively.¹⁹–²¹ If DBS enters your conversation, it's reasonable to ask: “What is the strongest evidence for this specific target, what are the known risks, and what are the unknowns that the study is trying to answer?”⁹,¹⁹–²¹ What are the main risks and burdens to understand before considering DBS research? Any brain surgery carries risk. Educational resources describe potential DBS risks such as bleeding in the brain, stroke, infection, seizures, and device or lead complications, along with the reality that additional visits are needed for programming and follow-up.¹⁷,²²,²³ DBS research also has practical burdens that deserve daylight: time commitment, travel, frequent monitoring, study rules about medication changes, and the emotional strain of hoping while living with uncertainty. Clinical trial listings can help you understand what is being studied and what participation involves.²⁴,²⁵ How do care pathways differ in the US versus other countries? Care pathways vary because guidelines, device approvals, and reimbursement policies differ. For example, NICE provides detailed recommendations for depression care in the UK and references interventional guidance for treatments like TMS and implanted VNS in specific contexts.³ In the US, FDA labeling, insurance coverage, and local availability shape access to options like TMS, esketamine, and VNS.¹³–¹⁶ If you live outside the US, a grounded question is: “Which national guideline applies to my care, and what referral pathway is used for neuromodulation treatments in my region?”³ What can you do before your next appointment to make care more effective? Bring a list of the diagnoses you have been given, psychotherapy types tried, medication names and doses, how long each was used, benefits, side effects, and why it stopped. Guidelines emphasize systematic review because it helps teams choose next steps with fewer repeats and fewer dead ends.²–⁴ You can also ask your medical team whether measurement-based care will be used, and which tool they prefer, such as the PHQ-9 or another validated scale.²,⁷,⁸ This can turn appointments into clearer checkpoints, not just survival stories recounted in a rush.²,⁷ What should you do if symptoms feel urgent or unsafe? If you feel at risk of harming yourself, if suicidal thoughts are escalating, or if symptoms are sudden, severe, or unmanageable, seek emergency care immediately. In the US, you can call or text 988 for the Suicide and Crisis Lifeline, and you can also call emergency services.²⁶ If you are supporting someone else, stay with them if possible, take threats or plans seriously, and contact emergency services or 988 for guidance.²⁶ SAFETY NOTE If symptoms are urgent, sudden, or severe, or if there is any risk of self-harm, seek emergency care immediately. In the US, call or text 988 for crisis support, or call emergency services.²⁶ GLOSSARY Adequate trial: A treatment attempt that is long enough, strong enough, and monitored enough to judge whether it helps. Augmentation: Adding a treatment, often a medication, to boost the effect of an antidepressant rather than replacing it. Cognitive behavioral therapy (CBT): A structured therapy that helps you notice unhelpful thought patterns and behaviors, then practice skills that support mood and functioning. Deep brain stimulation (DBS): A surgical treatment that implants electrodes in the brain to send controlled electrical pulses to specific circuits. Dissociation: A temporary feeling of being detached from yourself or your surroundings, sometimes described as feeling unreal or dreamlike. Electroconvulsive therapy (ECT): A procedure done under anesthesia that triggers a brief, controlled seizure to treat certain severe mental health conditions. Esketamine: A supervised nasal spray medication used for certain adults with treatment-resistant depression, with required monitoring. Major depressive disorder (MDD): A depressive condition defined by a pattern of symptoms that affect daily functioning. Measurement-based care: Using consistent symptom tracking tools over time to guide treatment decisions. PHQ-9: A short questionnaire often used to measure depression severity and track change over time. Recovery: Sustained remission over time, meaning improvement lasts rather than fading quickly. Remission: Depression symptoms are minimal or absent for a period of time. Response: A meaningful improvement in symptoms, even if some symptoms remain. Transcranial magnetic stimulation (TMS): A noninvasive clinic-based treatment that uses magnetic pulses to stimulate brain areas involved in mood. Treatment-resistant depression (TRD): Depression that has not improved enough after multiple well-delivered, evidence-based treatments. Vagus nerve stimulation (VNS): An implanted device that stimulates the vagus nerve to influence brain networks involved in mood and arousal. REFERENCE McIntyre RS, Alsuwaidan M, Baune BT, et al. Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions. World Psychiatry. 2023;22(3):394-412. doi:10.1002/wps.21120. https://onlinelibrary.wiley.com/doi/full/10.1002/wps.21120 Department of Veterans Affairs, Department of Defense. VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder. Version 4.0. 2022. https://www.healthquality.va.gov/guidelines/MH/mdd/VADODMDDCPGFinal508.pdf National Institute for Health and Care Excellence (NICE). Depression in adults: treatment and management (NG222). 2022; last reviewed 2024. https://www.nice.org.uk/guidance/ng222 Lam RW, Parikh SV, Michalak EE, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 updated clinical guidelines for the management of major depressive disorder in adults. Can J Psychiatry. 2024. doi:10.1177/07067437241245384. https://pmc.ncbi.nlm.nih.gov/articles/PMC11351064/ National Institute of Mental Health. Major Depression. https://www.nimh.nih.gov/health/statistics/major-depression National Institute of Mental Health. Depression. https://www.nimh.nih.gov/health/publications/depression Department of Veterans Affairs, Department of Defense. VA/DoD MDD Clinical Practice Guideline, Provider Summary (measurement-based care discussion). 2022. https://www.healthquality.va.gov/guidelines/MH/mdd/VADoDMDDCPG_ProviderSummary_Final_508_updated.pdf Kroenke K, Spitzer RL, Williams JBW. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606-613. doi:10.1046/j.1525-1497.2001.016009606.x. https://pmc.ncbi.nlm.nih.gov/articles/PMC1495268/ National Institute of Mental Health. Brain Stimulation Therapies. https://www.nimh.nih.gov/health/topics/brain-stimulation-therapies/brain-stimulation-therapies American Psychiatric Association. What is Electroconvulsive Therapy (ECT)? https://www.psychiatry.org/patients-families/ect Porter RJ, Douglas K, Jordan J, et al. Cognitive side-effects of electroconvulsive therapy: what are they, how to monitor them and what to tell patients. BJPsych Open. 2020;6(2):e40. doi:10.1192/bjo.2020.17. https://pmc.ncbi.nlm.nih.gov/articles/PMC7191622/ Mayo Clinic. Transcranial magnetic stimulation. 2023. https://www.mayoclinic.org/tests-procedures/transcranial-magnetic-stimulation/about/pac-20384625 U.S. Food and Drug Administration. 510(k) Substantial Equivalence Determination: NeuroStar TMS Therapy System (K083538). 2008. https://www.accessdata.fda.gov/cdrh_docs/pdf8/k083538.pdf U.S. Food and Drug Administration. SPRAVATO (esketamine) nasal spray, prescribing information. 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/211243s016lbl.pdf U.S. Food and Drug Administration. PMA Database: VNS Therapy System (P970003/S050). 2005. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=p970003s050 U.S. Food and Drug Administration. PMA approval order statement: VNS Therapy System indication (depression). 2005. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma_template.cfm?id=p970003s050 National Institute of Neurological Disorders and Stroke. Deep Brain Stimulation (DBS). 2025. https://www.ninds.nih.gov/health-information/disorders/deep-brain-stimulation-dbs Reddy S, Wall CA, Ghaemi SN, et al. Efficacy of deep brain stimulation for treatment-resistant depression: a systematic review and meta-analysis. J Affect Disord. 2024. https://www.sciencedirect.com/science/article/abs/pii/S2451902224002489 Giacobbe P, Mayberg HS, Lozano AM, et al. Deep brain stimulation to the subgenual cingulate gyrus for treatment-resistant depression: current evidence and future directions. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12578624/ Alagapan S, Choi KS, Heisig S, et al. Cingulate dynamics track depression recovery with deep brain stimulation. Nature. 2023. doi:10.1038/s41586-023-06541-3. https://www.nature.com/articles/s41586-023-06541-3 Himes LM, Riva-Posse P, Gross RE, Mayberg HS, et al. Revisiting subcallosal cingulate deep brain stimulation for depression: long-term follow-up and pooled outcomes. Brain Stimul. 2025. https://www.brainstimjrnl.com/article/S1935-861X%2825%2900310-9/fulltext Mayo Clinic. Deep brain stimulation. 2023. https://www.mayoclinic.org/tests-procedures/deep-brain-stimulation/about/pac-20384562 Lyons MK. Deep brain stimulation: current and future clinical applications. Mayo Clin Proc. 2011;86(7):662-672. https://www.mayoclinicproceedings.org/article/S0025-6196%2811%2960071-2/fulltext ClinicalTrials.gov. Deep Brain Stimulation for Major Depressive Disorder (example trial listing). https://clinicaltrials.gov/study/NCT00617162 ClinicalTrials.gov. Treatment ResistAnt Depression Subcallosal CingulatE (example trial listing). https://clinicaltrials.gov/study/NCT06423430 988 Suicide & Crisis Lifeline. https://988lifeline.org/

What is obsessive-compulsive disorder (OCD)? Obsessive-compulsive disorder (OCD) is a condition in which people experience obsessions, intrusive, unwanted thoughts, images, or urges, and compulsions, repeated behaviors or mental rituals done to reduce distress or to prevent a feared outcome.¹–⁴ Many people with OCD know the fear is bigger than the facts, but the feeling can still hit like an alarm that will not stop ringing.¹–³ OCD is not simply being neat, careful, or principled. Clinically, OCD is defined by distress, time burden, and interference with daily life, work, school, relationships, or health.¹,²,⁴ When the cycle is taking over your time and energy, that is a sign to seek an OCD-informed evaluation and evidence-based treatment.¹–⁴ What do “obsessions” and “compulsions” mean in plain language? Obsessions are unwanted mental intrusions. They can show up as a thought (“What if I contaminate someone?”), an image, or an urge, often paired with fear, disgust, guilt, or a powerful sense that something is “not right.”¹–⁶ The theme can vary, contamination, harm, taboo thoughts, religious scrupulosity, symmetry, health fears, relationship doubts, but the pattern is similar: the mind treats the thought like an emergency.¹–⁶ Compulsions are what people do to get relief or certainty. Some compulsions are visible, washing, cleaning, checking, repeating, arranging, seeking reassurance. Others are “mental compulsions,” like counting, repeating phrases, reviewing memories, or silently undoing a thought.¹–³,⁶ The relief can feel real but short-lived, and that temporary relief can train the brain to repeat the ritual again and again.¹,²,⁶ How does OCD affect the body, emotions, and daily functioning? OCD is not only “in the head.” The cycle can activate the body’s stress response, racing heart, muscle tension, nausea, trouble sleeping, and a constant background alertness.¹,²,⁴ Over time, people may start avoiding triggers, places, objects, or conversations, which can shrink life without anyone noticing at first.¹,²,⁴ OCD can also create moral pain. Many obsessions attack what a person values most, safety, faith, love, responsibility, and that can lead to shame and secrecy.²,³,⁶ An important clinical point is that having an intrusive thought is not the same as wanting it, and OCD treatment focuses on breaking the ritual cycle rather than debating whether you are a “good person.”²,³,⁶ How is OCD different from generalized anxiety, perfectionism, or obsessive-compulsive personality disorder (OCPD)? Generalized anxiety disorder often involves ongoing worries across many areas of life, such as health, finances, family, work. OCD tends to involve intrusive obsessions paired with ritual-like responses aimed at lowering distress or preventing a feared event.¹–³ The difference is not always obvious from the outside, so a careful assessment matters.¹–³ OCPD is also different. OCPD is a personality pattern that can include rigidity, perfectionism, and control, and it may feel aligned with “how things should be,” even when it causes problems. OCD, in contrast, often feels unwanted and distressing, though insight can vary and some people feel uncertain about whether their fears are reasonable.¹–³ If you have been given multiple labels, ask a clinician to explain which diagnosis best fits your symptoms and why, because treatment planning can change based on that distinction.²,³ What causes OCD, and what do clinicians mean by “brain circuitry”? OCD is understood as a mix of biology, brain networks, learning patterns, and life experience. It tends to run in families, and research supports the involvement of brain circuits linked to threat detection, error signals, and habit learning.¹–³ “Brain circuitry” does not mean your brain is broken. It means certain networks may be stuck in an overprotective loop, like a smoke alarm that is too sensitive. Evidence-based treatments aim to retrain the loop: ERP teaches the nervous system that distress can rise and fall without rituals, and medications can reduce symptom intensity enough to make that learning easier for some people.¹–³,²¹ How is OCD diagnosed, and what does a strong evaluation include? OCD is diagnosed clinically, meaning a trained professional uses a structured interview and your history to understand obsessions, compulsions, avoidance, distress, time spent, and impact on functioning.¹–⁴ A strong evaluation also looks for common co-occurring conditions, such as depression, other anxiety disorders, tic disorders, and substance use, because these can affect treatment choices and sequencing.¹–⁴ Many clinicians also use symptom rating scales to track severity and response over time. This is not about judging you. It is about tracking the pattern clearly, so treatment decisions are based on evidence of change rather than the memory of the hardest moment.¹,²,⁵,⁶ What is the Yale-Brown Obsessive Compulsive Scale (Y-BOCS), and why is it used so often? The Yale-Brown Obsessive Compulsive Scale (Y-BOCS) is a clinician-rated measure designed to assess OCD severity across different obsession themes and compulsion types. It evaluates factors such as time spent, distress, interference, resistance, and sense of control.⁵,⁶ Because it is structured and repeatable, it is widely used in both clinical care and research.⁵,⁶ The Y-BOCS can be especially helpful when OCD tries to hide progress. Someone might still feel anxious, but spend less time ritualizing, avoid fewer situations, or recover faster after a trigger. Those changes are clinically meaningful, and tools like the Y-BOCS help your team see them, name them, and build on them.²,⁵,⁶ What are the most effective first-line treatments for OCD? Across major guidelines and reputable organizations, two core first-line treatments stand out: cognitive behavioral therapy (CBT) that includes exposure and response prevention (ERP), and serotonin reuptake inhibitor medications, most commonly SSRIs.¹–⁴,⁹,²¹ These approaches are often used separately or together, depending on symptom severity, access to specialized therapy, and patient preference.¹–⁴ Stepped-care approaches recommend matching treatment intensity to functional impairment, then increasing intensity if response is limited. NICE guidance includes ERP-focused CBT, SSRI treatment, and combined therapy for more severe or impairing presentations.¹,⁴ What is exposure and response prevention (ERP), and how does it work? ERP is a specialized form of CBT that targets the OCD loop directly. “Exposure” means gradually and repeatedly facing triggers that spark obsessions. “Response prevention” means practicing not doing the compulsive behavior or mental ritual that would normally follow. Over time, the brain learns that anxiety and uncertainty can be tolerated, and compulsions are not required to stay safe.¹–³,⁴,²¹ Good ERP is collaborative and paced. Many clinicians use a hierarchy, a ladder of exposures from easier to harder, and practice between sessions so progress transfers into daily life.¹,²¹ If you tried therapy and it did not help, it is reasonable to ask whether the therapy included true ERP with response prevention, and whether the clinician has specific experience treating OCD.¹,²¹ What medications are commonly used for OCD, and how are medication trials typically structured? SSRIs are commonly used for OCD, and systematic reviews show SSRIs reduce OCD symptoms more than placebo.⁹ In clinical practice and guideline-based pathways, medication trials are planned and monitored, often with symptom measures like the Y-BOCS, and with attention to dose, time, side effects, and adherence.¹,⁴,¹⁰ Clomipramine is another evidence-based medication option for OCD. NICE guidance includes clomipramine as a consideration after an adequate SSRI trial is ineffective or not tolerated, while recognizing that side effect profiles and medical considerations can influence the choice.⁴,¹⁰ Any medication plan should include a shared understanding of what would count as improvement, what side effects matter most, and when reassessment will happen.¹,⁴,¹⁰ How long can it take to see meaningful improvement with ERP or medication? With ERP, improvement often appears first as behavioral change: fewer rituals, less avoidance, more willingness to sit with uncertainty. Anxiety may still show up, but the person becomes less controlled by it.¹–³,²¹ The pace varies, and structured practice between sessions is commonly emphasized as part of effective delivery.²¹ With medication, improvement can be gradual, and clinicians often stress the importance of an adequate, monitored trial rather than stopping too early.¹,⁴,¹⁰ If you want a practical way to talk about time, ask: “What is the planned trial length for this step, how will we measure change, and what is the plan if improvement is partial?”¹,⁴,⁵,¹⁰ What does “treatment-resistant OCD” mean? There is no single universal definition, and different clinics and studies use different thresholds. In many real-world care pathways, “treatment-resistant” or “treatment-refractory” OCD generally means symptoms remain severe and impairing despite adequate trials of evidence-based first-line treatments, especially ERP-based CBT and appropriate medication trials.⁴,¹⁰,¹¹ Because definitions vary, it helps to make the criteria explicit with your clinician. Ask what counts as “adequate ERP,” whether past therapy truly included response prevention, what medication doses and durations were tried, and whether symptoms were tracked with a consistent measure like the Y-BOCS.⁴–⁶,¹⁰ What are common next-step treatments when first-line OCD care is not enough? Next-step care often focuses on optimization rather than simply “trying something new.” That can include intensifying ERP with an OCD specialist, addressing avoidance and family accommodation, refining medication strategy, and considering augmentation, adding a medication to strengthen an SSRI or clomipramine effect rather than switching immediately.⁴,¹⁰,¹¹ Some people also explore neuromodulation options when OCD remains severe despite multiple steps. Those conversations usually happen in specialty settings and should include clear discussion of expected benefits, side effects, time commitment, and how response will be measured.¹,⁴,¹⁰,¹³–¹⁶ What is medication augmentation for OCD, and what does the evidence show? Augmentation means adding a medication to boost the effect of an existing serotonin reuptake inhibitor regimen. Meta-analyses of randomized, placebo-controlled trials support antipsychotic augmentation for a subset of people with SRI-resistant OCD, while also showing that not everyone benefits.¹¹,¹² Because the benefits are probabilistic and side effects can be significant, augmentation decisions should be paired with a clear monitoring plan and a defined reassessment window. If augmentation is proposed, helpful questions include: “What symptom change would count as success, how long will we try it, and what metabolic or movement-related side effects are we monitoring?”¹¹–¹³ What is transcranial magnetic stimulation (TMS) for OCD, and what does FDA status mean? TMS is a noninvasive procedure that uses magnetic fields to stimulate nerve cells in the brain. The FDA permitted marketing of TMS for OCD, which reflects a regulatory decision based on evidence for a specific device and protocol.¹³ In practice, TMS for OCD is delivered over multiple sessions, and reputable OCD organizations note that specific “recipes,” meaning device type, target, and protocol, matter for what is considered FDA-cleared.¹³,²² TMS does not require surgery, but it is still a medical intervention with risks and side effects. Educational medical center resources describe common side effects such as headache and scalp discomfort, and they note that seizure is a rare risk that clinics screen for.¹⁴ If TMS is being considered, it is reasonable to ask which protocol is used for OCD, how many sessions are typical, what side effects are most common at that center, and how response will be tracked.¹³,¹⁴,²² What is deep brain stimulation (DBS) for OCD, and what is its regulatory status in the US? DBS is a surgical therapy that implants electrodes in targeted brain regions and connects them to an implanted pulse generator.¹⁶ In the US, the FDA lists a Humanitarian Device Exemption (HDE) indication for a DBS system for chronic, severe, treatment-resistant OCD in adults, specifically for bilateral stimulation of the anterior limb of the internal capsule as an adjunct to medications and as an alternative to anterior capsulotomy, for patients who have failed multiple SSRI trials.¹⁷ An HDE is not the same as broad FDA approval, and access is usually limited to specialized centers. The decision to consider DBS typically follows careful documentation of multiple evidence-based treatments, and it should involve a detailed informed consent process that covers surgical risks, device management, follow-up burden, and realistic uncertainty about outcomes.¹⁶,¹⁷ What does research suggest about DBS outcomes for severe, treatment-resistant OCD? Systematic reviews and meta-analyses generally report that DBS can reduce OCD symptom severity for some people with severe, treatment-resistant OCD, commonly measured by changes in Y-BOCS scores, though outcomes vary widely across individuals and studies.¹⁸,¹⁹ Reviews focusing on sham-controlled trial phases also suggest benefit compared with sham in certain datasets, while emphasizing limitations such as small sample sizes and differences in targets and protocols.¹⁹,²⁰ Uncertainty remains a central part of the story. Reviews describe ongoing questions about who benefits most, which brain targets are optimal, how programming should be adjusted over time, and how to balance benefit with side effects.¹⁸–²⁰ If DBS enters your conversation, consider asking your medical team the following: “What target does this center use, what evidence supports it, what is the expected programming timeline, and what outcomes define meaningful improvement here?”¹⁷–²⁰ What are the key risks and long-term commitments for TMS and DBS? TMS is noninvasive, but it requires frequent visits and consistent attendance for a full course. Medical center resources describe common side effects such as headache and scalp discomfort, and they note rare seizure risk.¹⁴ DBS is invasive and involves implanted hardware. Educational neurology resources describe risks including bleeding in the brain, infection, seizures, and device-related complications, along with long-term follow-up for programming and device care.¹⁶ If you are considering DBS, ask the team to describe the follow-up schedule, what happens if symptoms worsen, and what support exists if the initial programming does not help.¹⁶–¹⁸ How can you prepare for an OCD appointment so care is more targeted? Bring a symptom map. Include: your main obsession themes, your main compulsions and mental rituals, what you avoid, how much time OCD takes daily, and what situations trigger spikes.¹–⁴ This helps your clinician build an ERP plan that fits your actual triggers, not a generic template.¹,²¹ Bring a treatment history with your specifics: whether therapy included ERP with response prevention, what medications were tried, what doses and durations, what helped, what side effects occurred, and why trials ended.¹,⁴,¹⁰ If your clinic uses the Y-BOCS or another measure, ask how often it will be repeated and how it will guide decisions.⁵,⁶,¹⁰ How can care partners help without accidentally strengthening OCD? OCD can pull families into rituals through reassurance, checking, or helping someone avoid triggers. NICE guidance includes attention to family and carer needs, and OCD organizations encourage learning how to support ERP goals rather than feeding compulsions.⁴,²¹ A practical next step is to ask the treating clinician or therapist for a family plan: which responses are supportive, which responses reinforce compulsions, and what phrases can reduce conflict while still supporting ERP.⁴,²¹ If you are a care partner, it is also reasonable to ask where you can get support, because chronic accommodation can exhaust the whole household.⁴ What should you do if symptoms feel urgent, unsafe, or out of control? If you feel at risk of harming yourself, if suicidal thoughts are escalating, or if symptoms are sudden, severe, or unmanageable, seek emergency care immediately. In the US, you can call or text 988 for the Suicide and Crisis Lifeline, and you can also contact emergency services.²³ If you are supporting someone else, stay with them if possible, take threats or plans seriously, and contact emergency services or 988 for guidance.²³ When the mind feels like floodwater rising fast, urgent help is the safest door to reach for.²³ GLOSSARY Anterior limb of the internal capsule (ALIC): A bundle of brain pathways involved in communication between brain regions, used as a DBS target in some severe cases of OCD. Augmentation: Adding a medication or treatment to boost the effect of an existing treatment rather than replacing it. Care partner: A family member or friend who supports a person living with a health condition. Cognitive behavioral therapy (CBT): A structured therapy that helps change patterns of thoughts and behaviors that maintain symptoms. Compulsions: Repeated behaviors or mental rituals done to reduce distress, to feel “certain,” or to prevent a feared outcome. Deep brain stimulation (DBS): A surgical therapy that implants electrodes in the brain to deliver controlled electrical stimulation to specific circuits. Deep TMS: A form of TMS that uses a coil designed to stimulate broader brain regions than standard coils. Exposure: In ERP, the planned practice of facing triggers that spark obsessions in a gradual, structured way. Exposure and response prevention (ERP): A form of CBT that reduces OCD by pairing exposure to triggers with practicing not doing compulsions. Humanitarian Device Exemption (HDE): An FDA pathway that allows certain devices for conditions affecting relatively small populations, with specific requirements and limits. Insight: How strongly a person believes OCD fears might be true, which can range from good insight to very limited insight. Mental rituals: Compulsions that happen internally, such as counting, repeating phrases, reviewing memories, or trying to “feel certain.” Obsessions: Intrusive, unwanted thoughts, images, or urges that cause distress. Response prevention: In ERP, the practice of not performing compulsions after an obsession is triggered. Selective serotonin reuptake inhibitor (SSRI): A common medication class that affects serotonin signaling and is often used as a first-line medicine for OCD. Serotonin reuptake inhibitor (SRI): A broader group that includes SSRIs and clomipramine, often used for OCD. Stepped care: A care approach that starts with effective options matched to severity, then increases intensity based on need and response. Transcranial magnetic stimulation (TMS): A noninvasive treatment that uses magnetic pulses to influence brain activity. Treatment-resistant OCD: OCD that remains severe and impairing despite adequate trials of evidence-based treatments such as ERP and medication. Yale-Brown Obsessive Compulsive Scale (Y-BOCS): A clinician-rated scale used to measure OCD severity and track change over time. REFERENCES National Institute of Mental Health. Obsessive-Compulsive Disorder (OCD). https://www.nimh.nih.gov/health/topics/obsessive-compulsive-disorder-ocd National Institute of Mental Health. Obsessive-Compulsive Disorder: When Unwanted Thoughts or Repetitive Behaviors Take Over. https://www.nimh.nih.gov/health/publications/obsessive-compulsive-disorder-when-unwanted-thoughts-or-repetitive-behaviors-take-over American Psychiatric Association. What Is Obsessive-Compulsive Disorder? https://www.psychiatry.org/patients-families/obsessive-compulsive-disorder/what-is-obsessive-compulsive-disorder Mayo Clinic. Obsessive-compulsive disorder (OCD): Symptoms and causes. https://www.mayoclinic.org/diseases-conditions/obsessive-compulsive-disorder/symptoms-causes/syc-20354432 Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry. 1989;46(11):1006-1011. https://jamanetwork.com/journals/jamapsychiatry/fullarticle/494743 Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale. II. Validity. Arch Gen Psychiatry. 1989;46(11):1012-1016. https://pubmed.ncbi.nlm.nih.gov/2510699/ National Institute for Health and Care Excellence (NICE). Obsessive-compulsive disorder and body dysmorphic disorder: treatment (CG31), Recommendations. https://www.nice.org.uk/guidance/cg31/chapter/Recommendations Soomro GM, Altman D, Rajagopal S, Oakley-Browne M. Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD). Cochrane Database Syst Rev. 2008;(1):CD001765. doi:10.1002/14651858.CD001765.pub3. https://pmc.ncbi.nlm.nih.gov/articles/PMC7025764/ Cochrane Library. Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD). https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001765.pub3/abstract Kayser RR, Erwin AM, Feusner JD, et al. Pharmacotherapy for treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry. 2020;81(6):19r13025. https://pmc.ncbi.nlm.nih.gov/articles/PMC7495343/ Dold M, Aigner M, Lanzenberger R, Kasper S. Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomized, placebo-controlled trials. Int J Neuropsychopharmacol. 2013;16(3):557-574. doi:10.1017/S1461145712000740. https://academic.oup.com/ijnp/article/16/3/557/649596 Veale D, Miles S, Smallcombe N, Ghezai H, Goldacre B, Hodsoll J. Atypical antipsychotic augmentation in SSRI treatment refractory obsessive-compulsive disorder: a systematic review and meta-analysis. BMC Psychiatry. 2014;14:317. https://pubmed.ncbi.nlm.nih.gov/25432131/ U.S. Food and Drug Administration. FDA permits marketing of transcranial magnetic stimulation for treatment of obsessive compulsive disorder. https://www.fda.gov/news-events/press-announcements/fda-permits-marketing-transcranial-magnetic-stimulation-treatment-obsessive-compulsive-disorder Mayo Clinic. Transcranial magnetic stimulation. https://www.mayoclinic.org/tests-procedures/transcranial-magnetic-stimulation/about/pac-20384625 National Institute of Mental Health. Brain Stimulation Therapies. https://www.nimh.nih.gov/health/topics/brain-stimulation-therapies/brain-stimulation-therapies National Institute of Neurological Disorders and Stroke. Deep Brain Stimulation (DBS). https://www.ninds.nih.gov/health-information/disorders/deep-brain-stimulation-dbs U.S. Food and Drug Administration. Humanitarian Device Exemption (HDE): Approval for the Reclaim DBS Therapy for Obsessive Compulsive Disorder (OCD). https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfhde/hde.cfm?id=375533 Gadot R, Richter EO, Meng Y, et al. Efficacy of deep brain stimulation for treatment-resistant obsessive-compulsive disorder: systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2022;93(11):1166-1173. https://jnnp.bmj.com/content/93/11/1166 Cohen SE, Sheth SA, Nuttin B, et al. Deep brain stimulation for obsessive-compulsive disorder: a systematic review and meta-analysis of sham-controlled trials. Nat Ment Health. 2025. https://pubmed.ncbi.nlm.nih.gov/40579425/ Fanty L, Nuttin B, Tyagi H, et al. The current state, challenges, and future directions of deep brain stimulation for refractory obsessive-compulsive disorder. Expert Rev Neurother. 2023. https://www.tandfonline.com/doi/full/10.1080/17434440.2023.2252732 International OCD Foundation. Exposure and Response Prevention (ERP). https://iocdf.org/about-ocd/treatment/erp/ International OCD Foundation. Transcranial Magnetic Stimulation (TMS) for OCD. https://iocdf.org/about-ocd/treatment/tms/ 988 Suicide & Crisis Lifeline. https://988lifeline.org/

What do clinicians mean by “substance use disorder” and “addiction”? Substance use disorder (SUD) is a medical diagnosis that describes a pattern of substance use that causes significant problems in health, daily life, relationships, work, school, or safety.¹,² The word “addiction” is often used to describe the more severe end of the SUD spectrum, where substance use becomes compulsive and hard to control despite harmful consequences.¹ Many reputable medical organizations describe addiction as a chronic, relapsing disorder that involves changes in brain circuits related to reward, stress, and self-control.¹ This framing is not meant to take away personal responsibility, it's meant to explain why willpower alone is often not enough, and why evidence-based treatment matters.¹,² What is the difference between use, unhealthy use, dependence, and addiction? People use substances for many reasons, and not all use equals a disorder. Screening guidance in primary care often uses terms like “unhealthy” use to describe patterns that increase risk for harm, even if a full SUD diagnosis is not present.³,⁴ Physical dependence is also not the same as addiction. Dependence means the body has adapted, so stopping suddenly can cause withdrawal symptoms. Addiction, in contrast, centers on loss of control, compulsive use, and continued use despite significant negative consequences.¹,¹⁴ This distinction is especially important for prescribed medications like opioids or benzodiazepines, where dependence can occur even when taken as directed.¹⁴ Why can stopping be so hard, even when someone truly wants to stop? Addiction is associated with functional changes in brain circuits involved in reward, stress response, and self-control, and those changes can persist even after someone stops using.¹ This can make cravings feel loud and urgent, like a wave that rises fast and blocks out everything else.¹,² Relapse is also common in many chronic conditions, and in SUD it often reflects the need for more treatment support, different strategies, or a safer level of care, not a moral failure.¹,² A key goal of treatment is building stability and safety while reducing the power that triggers, stress, and withdrawal symptoms can have over behavior.¹,² What are common signs that substance use may be turning into a disorder? SUD often shows up as a pattern, not a single moment. Signs can include using more than intended, repeated unsuccessful efforts to cut down, spending a lot of time obtaining or using the substance, cravings, and continuing use even when it harms health, relationships, or responsibilities.¹,² Other common signs include tolerance (needing more to get the same effect), withdrawal symptoms when stopping, and narrowing of life, where hobbies, relationships, and routines slowly get replaced by substance-centered planning.¹,² If you are unsure whether your pattern fits SUD, it is reasonable to ask for a screening conversation in primary care, especially since the USPSTF recommends screening adults by asking questions when follow-up services are available.³,⁴ How is substance use disorder diagnosed, and what does a strong evaluation include? SUD is diagnosed through a clinical evaluation, usually a structured conversation about what substances are used, how often, how much, and what consequences are occurring.¹,² A strong evaluation also reviews physical health, mental health, sleep, pain, trauma exposure, medications, and safety risks, including overdose risk.²,⁵ Co-occurring mental health conditions are common in SUD, and integrated care often improves outcomes.² When both mental health symptoms and substance use are present, it helps to ask clinicians to clarify the timeline, what came first, what worsens what, and how treatment will address both together rather than treating them as separate rooms with separate doors.² What treatments work best overall, across different substances? Across many forms of SUD, the strongest approach is usually a combination of evidence-based behavioral therapies, recovery supports, and, when indicated, medications that reduce cravings, withdrawal, or relapse risk.¹,²,⁶ This can happen in outpatient care, intensive outpatient programs, residential treatment, or hospital-based care, depending on severity and safety.² Good treatment is also personalized. It may include help with housing, employment, transportation, legal needs, and family support, because stability is often part of recovery biology, steady ground under the feet helps the brain heal.² If you are deciding on a level of care, ask: “What risks make outpatient unsafe right now, and what would make it safe again?”²,⁷ What are evidence-based medication options for opioid use disorder (OUD)? Medications for opioid use disorder (MOUD) are evidence-based treatments that include buprenorphine, methadone, and naltrexone.⁵,⁶,⁸ CDC clinical guidance notes that medication treatment for OUD has been associated with reduced overdose risk and reduced overall mortality, and clinicians should offer or arrange evidence-based treatment.⁵ Guidelines and federal resources emphasize that MOUD is not “replacing one drug with another.” These medications are prescribed in controlled ways that reduce withdrawal and cravings, support recovery stability, and lower risk of overdose.⁵,⁶,⁸ If MOUD is being considered, helpful questions include: “Which option fits my situation, what are the pros and cons, what follow-up is required, and what would we do if cravings break through?”⁵,⁶,⁸ What are evidence-based treatments for alcohol use disorder (AUD)? AUD treatment commonly includes behavioral therapies and mutual-support approaches, and for some people it also includes FDA-approved medications.¹¹,¹² NIAAA notes three FDA-approved medications for AUD: disulfiram, acamprosate, and naltrexone.¹¹ The American Psychiatric Association guideline provides evidence-based recommendations for pharmacologic treatment choices in outpatient care.¹² Withdrawal safety is also a critical part of AUD care. ASAM’s alcohol withdrawal guideline emphasizes evidence-based strategies and standards for alcohol withdrawal management, and it also underscores that withdrawal management alone is not treatment for AUD.⁷ In plain terms: detox can be a doorway, but recovery treatment is the path beyond the doorway.⁷,¹² What withdrawal situations can be dangerous or life-threatening? Some withdrawals can be medically dangerous, especially alcohol withdrawal and benzodiazepine withdrawal, which can involve severe symptoms and may require medical management.⁷,¹³,¹⁴ MedlinePlus describes delirium tremens as a severe form of alcohol withdrawal with sudden and severe nervous system changes.¹³ For benzodiazepines, clinical guidance emphasizes that people who have been taking them regularly should not stop abruptly and should taper under clinical supervision to reduce withdrawal risks.¹⁴ If you or someone you care about is considering stopping alcohol or sedatives after heavy or long-term use, it is reasonable to ask a clinician: “What is the safest way to reduce, what warning signs require urgent care, and what level of monitoring is appropriate?”⁷,¹⁴ What about stimulant (cocaine or methamphetamine) use disorder, and what treatments have the best evidence? For stimulant use disorder, evidence-based behavioral treatments are central. Contingency management (CM), a structured approach that provides tangible reinforcement for treatment goals, is repeatedly described by federal and policy sources as an evidence-based intervention for stimulant use disorder.¹⁵,¹⁶ ASAM’s stimulant use disorder guideline provides clinical recommendations for assessment and treatment approaches.¹⁷ CM is a behavioral learning strategy grounded in how reinforcement changes habits and decision patterns over time.¹⁵–¹⁷ If CM is available, you can ask: “What behaviors are reinforced, how long does the program run, and how are progress and setbacks handled?”¹⁵–¹⁷ Can deep brain stimulation (DBS) treat addiction? At this time, DBS is not an established, broadly approved treatment for substance use disorder in the US, although it has been successfully used for treatment in Canad. Research has explored DBS targets involved in reward and craving, and recent reviews describe this work as experimental with limited and heterogeneous evidence.¹⁹,²⁰ Some clinical research, including early feasibility studies, has investigated DBS for severe, treatment-refractory OUD and reported signals that DBS may reduce substance use and craving in carefully selected participants, but these findings are early and do not mean DBS is appropriate or available for most people with SUD.²⁰ If DBS is ever raised in your care, consider asking: “Is this part of a clinical trial, what are the eligibility criteria, what are the known risks, and what evidence supports this approach for my specific situation?”¹⁹,²⁰ SAFETY NOTE If symptoms are urgent, sudden, or severe, seek emergency care immediately. If you think someone is overdosing or not breathing normally, call emergency services right away, and use naloxone if it is available.⁹,¹⁰ GLOSSARY Addiction: A severe form of substance use disorder marked by compulsive use and continued use despite harm. Alcohol use disorder (AUD): A medical diagnosis describing a problematic pattern of alcohol use that causes distress or impairment. Benzodiazepines: A class of sedative medications often prescribed for anxiety, seizures, or insomnia; stopping suddenly after regular use can cause withdrawal risks. Behavioral therapy: A structured counseling approach that builds skills to change habits, cope with cravings, and reduce relapse risk. Contingency management (CM): A behavioral treatment that uses positive reinforcement to support recovery goals, often used for stimulant use disorder. Craving: A strong urge to use a substance, often triggered by stress, cues, or withdrawal sensations. Detoxification (withdrawal management): Medical support for safely managing withdrawal symptoms; it is not the same as long-term treatment. Deep brain stimulation (DBS): A surgical therapy that delivers electrical stimulation to specific brain circuits; for SUD it remains investigational. Harm reduction: Practical strategies that reduce injury and death while a person remains at risk, such as naloxone access and overdose response planning. Medications for opioid use disorder (MOUD): FDA-approved medications such as buprenorphine, methadone, and naltrexone used to treat opioid use disorder. Naloxone: A medication that can reverse an opioid overdose. Opioid use disorder (OUD): A substance use disorder involving opioids such as heroin, fentanyl, or prescription opioid medications. Physical dependence: A body adaptation where stopping a substance suddenly can cause withdrawal symptoms; this can occur with prescribed medicines. Relapse: A return to substance use after a period of stopping or reducing use; often signals the need for more or different treatment support. Screening: Brief questions used in healthcare settings to identify unhealthy substance use and guide next steps. Substance use disorder (SUD): A medical diagnosis describing ongoing substance use that causes distress or functional impairment. Withdrawal: Physical and mental symptoms that can occur when a substance is reduced or stopped after the body has adapted to it. REFERENCES National Institute on Drug Abuse (NIDA). Drug misuse and addiction. https://nida.nih.gov/publications/drugs-brains-behavior-science-addiction/drug-misuse-addiction Substance Abuse and Mental Health Services Administration (SAMHSA). Substance Use Disorder Treatment for People With Co-Occurring Disorders (TIP 42), Updated 2020. https://www.ncbi.nlm.nih.gov/books/NBK571020/ US Preventive Services Task Force. Recommendation: Unhealthy Drug Use, Screening. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/drug-use-illicit-screening US Preventive Services Task Force. Recommendation: Unhealthy Alcohol Use in Adolescents and Adults, Screening and Behavioral Counseling Interventions. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/unhealthy-alcohol-use-in-adolescents-and-adults-screening-and-behavioral-counseling-interventions Centers for Disease Control and Prevention (CDC). Opioid Use Disorder, Treating. https://www.cdc.gov/overdose-prevention/hcp/clinical-care/opioid-use-disorder-treating.html Substance Abuse and Mental Health Services Administration (SAMHSA). TIP 63: Medications for Opioid Use Disorder. https://library.samhsa.gov/sites/default/files/pep21-02-01-002.pdf American Society of Addiction Medicine (ASAM). The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management. https://www.asam.org/docs/default-source/quality-science/the_asam_clinical_practice_guideline_on_alcohol-1.pdf National Institute on Drug Abuse (NIDA). Medications for Opioid Use Disorder. https://nida.nih.gov/research-topics/medications-opioid-use-disorder Centers for Disease Control and Prevention (CDC). Lifesaving Naloxone. https://www.cdc.gov/stop-overdose/caring/naloxone.html Substance Abuse and Mental Health Services Administration (SAMHSA). Overdose Prevention and Response Toolkit. https://library.samhsa.gov/sites/default/files/overdose-prevention-response-kit-pep23-03-00-001.pdf National Institute on Alcohol Abuse and Alcoholism (NIAAA). Medications Development Program. https://www.niaaa.nih.gov/medications-development-program Reus VI, Fochtmann LJ, Bukstein O, et al. The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder. Am J Psychiatry. 2018;175(1):86-90. doi:10.1176/appi.ajp.2017.1750101. https://pubmed.ncbi.nlm.nih.gov/29301420/ MedlinePlus. Delirium tremens. https://medlineplus.gov/ency/article/000766.htm American Society of Addiction Medicine (ASAM). Joint Clinical Practice Guideline on Benzodiazepine Tapering. https://downloads.asam.org/sitefinity-production-blobs/docs/default-source/guidelines/benzodiazepine-tapering-2025/bzd-tapering-document---final-approved-version-for-distribution-02-28-25.pdf Office of the Assistant Secretary for Planning and Evaluation (ASPE), US Department of Health and Human Services. Contingency Management for the Treatment of Substance Use Disorders. https://aspe.hhs.gov/reports/contingency-management-treatment-suds Substance Abuse and Mental Health Services Administration (SAMHSA). Using SAMHSA Funds to Implement Evidence-Based Contingency Management Services (PEP24-06-001). https://library.samhsa.gov/sites/default/files/contingency-management-advisory-pep24-06-001.pdf American Society of Addiction Medicine (ASAM). Management of Stimulant Use Disorder. https://downloads.asam.org/sitefinity-production-blobs/docs/default-source/quality-science/stud_guideline_document_final.pdf Centers for Disease Control and Prevention (CDC). Quit Smoking Medicines. https://www.cdc.gov/tobacco/campaign/tips/quit-smoking/quit-smoking-medications/how-to-use-quit-smoking-medicines/index.html Zammit Dimech D, Carter A, et al. A systematic review of deep brain stimulation for substance use disorders. Transl Psychiatry. 2024. https://www.nature.com/articles/s41398-024-03060-1 Rezai AR, et al. Safety and feasibility clinical trial of nucleus accumbens deep brain stimulation for treatment-refractory opioid use disorder. J Neurosurg. 2023. https://thejns.org/view/journals/j-neurosurg/140/1/article-p231.xml Substance Abuse and Mental Health Services Administration (SAMHSA). SAMHSA’s National Helpline. https://www.samhsa.gov/find-help/helplines/national-helpline